Urothelial bladder cancer: biomarkers for detection and screening
2008; Wiley; Volume: 102; Issue: 9b Linguagem: Inglês
10.1111/j.1464-410x.2008.07965.x
ISSN1464-410X
AutoresBadrinath R. Konety, Yair Lotan,
Tópico(s)Urinary and Genital Oncology Studies
ResumoBJU InternationalVolume 102, Issue 9b p. 1234-1241 Urothelial bladder cancer: biomarkers for detection and screening Badrinath Konety, Badrinath Konety Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA, and Urology, University of Texas Southwestern Medical Center, Dallas, TX, USASearch for more papers by this authorYair Lotan, Corresponding Author Yair Lotan Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA, and Urology, University of Texas Southwestern Medical Center, Dallas, TX, USAYair Lotan, Department of Urology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390–9110, USA. e-mail: [email protected]Search for more papers by this author Badrinath Konety, Badrinath Konety Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA, and Urology, University of Texas Southwestern Medical Center, Dallas, TX, USASearch for more papers by this authorYair Lotan, Corresponding Author Yair Lotan Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA, and Urology, University of Texas Southwestern Medical Center, Dallas, TX, USAYair Lotan, Department of Urology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390–9110, USA. e-mail: [email protected]Search for more papers by this author First published: 15 October 2008 https://doi.org/10.1111/j.1464-410X.2008.07965.xCitations: 17Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66 10.3322/canjclin.57.1.43 CASPubMedWeb of Science®Google Scholar 2 Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945; 18: 519–20 10.1126/science.101.2629.519 Web of Science®Google Scholar 3 Paez A, Coba JM, Murillo N et al. Reliability of the routine cytological diagnosis in bladder cancer. Eur Urol 1999; 35: 228–32 10.1159/000019851 CASPubMedWeb of Science®Google Scholar 4 Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002; 167: 75–9 10.1016/S0022-5347(05)65386-4 PubMedWeb of Science®Google Scholar 5 Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61: 109–18 10.1016/S0090-4295(02)02136-2 PubMedWeb of Science®Google Scholar 6 Keesee SK, Briggman JV, Thill G et al. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996; 6: 189–214 10.1615/CritRevEukarGeneExpr.v6.i2-3.50 CASPubMedWeb of Science®Google Scholar 7 Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80–3 10.1016/S0022-5347(05)65387-6 PubMedWeb of Science®Google Scholar 8 Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293: 810–6 10.1001/jama.293.7.810 CASPubMedWeb of Science®Google Scholar 9 Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295: 299–305 10.1001/jama.295.3.299 CASPubMedWeb of Science®Google Scholar 10 Miyanaga N, Akaza H, Ishikawa S et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163–8 10.1159/000474443 CASPubMedWeb of Science®Google Scholar 11 Atsu N, Ekici S, Oge OO et al. False-positive results of the NMP22 test due to hematuria. J Urol 2002; 167: 555–8 10.1016/S0022-5347(01)69084-0 PubMedWeb of Science®Google Scholar 12 Ishii T, Okadome A, Takeuchi F et al. Urinary levels of nuclear matrix protein 22 in patients with urinary diversion. Urology 2001; 58: 940–2 10.1016/S0090-4295(01)01404-2 CASPubMedWeb of Science®Google Scholar 13 Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. BJU Int 2007; 177: 1636–45 PubMedWeb of Science®Google Scholar 14 Tritschler S, Scharf S, Karl A et al. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007; 51: 403–8 10.1016/j.eururo.2006.08.001 CASPubMedWeb of Science®Google Scholar 15 Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000; 27: 63–73 10.1016/S0094-0143(05)70235-4 CASPubMedWeb of Science®Google Scholar 16 Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006; 24: 326–37 10.1016/j.urolonc.2005.11.023 CASPubMedWeb of Science®Google Scholar 17 Landman J, Chang Y, Kavaler E et al. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52: 398–402 10.1016/S0090-4295(98)00219-2 CASPubMedWeb of Science®Google Scholar 18 Johnston B, Morales A, Emerson L et al. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098–101 10.1016/S0022-5347(01)68166-7 CASPubMedWeb of Science®Google Scholar 19 Oge O, Atsu N, Sahin A et al. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer. Scand J Urol Nephrol 2000; 34: 349–51 10.1080/003655900455404 CASPubMedWeb of Science®Google Scholar 20 Zimmerman RL, Bagley D, Hawthorne C et al. Utility of the Bard BTA test in detecting upper urinary tract transitional cell carcinoma. Urology 1998; 51: 956–8 10.1016/S0090-4295(98)00115-0 CASPubMedWeb of Science®Google Scholar 21 Raitanen MP, Hellström P, Marttila T et al. Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test. Eur Urol 2001; 40: 422–6 10.1159/000049810 CASPubMedWeb of Science®Google Scholar 22 Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunocytTM. Can J Urol 1997; 4: 400–5 PubMedGoogle Scholar 23 Fradet Y, LaRue H, Parent-Vaugeois C et al. Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas. Int J Cancer 1990; 46: 990–7 10.1002/ijc.2910460607 CASPubMedWeb of Science®Google Scholar 24 Fradet Y, Islam N, Boucher L et al. Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 7227–31 10.1073/pnas.84.20.7227 CASPubMedWeb of Science®Google Scholar 25 Allard P, Fradet Y, Tetu B et al. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995; 1: 1195–202 CASPubMedWeb of Science®Google Scholar 26 Vriesema JL, Atsma F, Kiemeney LA et al. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001; 58: 367–71 10.1016/S0090-4295(01)01217-1 CASPubMedWeb of Science®Google Scholar 27 Lodde M, Mian C, Wiener H et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology 2001; 58: 362–6 10.1016/S0090-4295(01)01182-7 CASPubMedWeb of Science®Google Scholar 28 Piaton E, Daniel L, Verriele V et al. Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest 2003; 83: 845–52 10.1097/01.LAB.0000074893.70675.2E CASPubMedWeb of Science®Google Scholar 29 Lodde M, Mian C, Negri G et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 2003; 61: 243–7 10.1016/S0090-4295(02)02073-3 PubMedWeb of Science®Google Scholar 30 Feil G, Zumbragel A, Paulgen-Nelde HJ et al. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder. Anticancer Res 2003; 23: 963–7 CASPubMedWeb of Science®Google Scholar 31 Messing EM, Teot L, Korman H et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 2005; 174: 1238–41 10.1097/01.ju.0000173918.84006.4d PubMedWeb of Science®Google Scholar 32 Mian C, Maier K, Comploj E et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006; 108: 60–5 10.1002/cncr.21712 CASPubMedWeb of Science®Google Scholar 33 Pfister C, Chautard D, Devonec M et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003; 169: 921–4 10.1097/01.ju.0000048983.83079.4c PubMedWeb of Science®Google Scholar 34 Lodde M, Mian C, Comploj E et al. The uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006; 67: 950–4 10.1016/j.urology.2005.11.057 PubMedWeb of Science®Google Scholar 35 Mian C, Lodde M, Comploj E et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 2005; 25: 3641–4 PubMedWeb of Science®Google Scholar 36 Cajulis RS, Haines GK 3rd , Frias-Hidvegi D et al. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995; 13: 214–23 10.1002/dc.2840130307 CASPubMedWeb of Science®Google Scholar 37 Placer J, Espinet B, Salido M et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002; 42: 547–52 10.1016/S0302-2838(02)00448-7 PubMedWeb of Science®Google Scholar 38 Toma MI, Friedrich MG, Hautmann SH et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004; 22: 145–9 10.1007/s00345-003-0390-8 PubMedWeb of Science®Google Scholar 39 Varella-Garcia M, Akduman B, Sunpaweravong P et al. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol 2004; 22: 16–9 10.1016/S1078-1439(03)00098-X PubMedWeb of Science®Google Scholar 40 Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168: 1950–4 10.1016/S0022-5347(05)64270-X CASPubMedWeb of Science®Google Scholar 41 Schwarz S, Rechenmacher M, Filbeck T et al. Value of multicolor fluorescence in situ hybridization (Urovysion TM) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 2008; 61: 272–7 10.1136/jcp.2007.049684 CASPubMedWeb of Science®Google Scholar 42 Bergman J, Reznichek RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int 2008; 101: 26–9 10.1111/j.1464-410X.2007.07183.x PubMedWeb of Science®Google Scholar 43 Zellweger T, Benz G, Cathomas G et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006; 119: 1660–5 10.1002/ijc.21704 CASPubMedWeb of Science®Google Scholar 44 Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169: 2101–5 10.1097/01.ju.0000066842.45464.cc CASPubMedWeb of Science®Google Scholar 45 Yoder BJ, Skacel M, Hedgepeth R et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127: 295–301 10.1309/ADJL7E810U1H42BJ PubMedWeb of Science®Google Scholar 46 Bollmann M, Heller H, Bankfalvi A et al. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005; 95: 1219–25 10.1111/j.1464-410X.2005.05509.x CASPubMedWeb of Science®Google Scholar 47 Mian C, Lodde M, Comploj E et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006; 59: 984–7 10.1136/jcp.2005.035394 CASPubMedWeb of Science®Google Scholar 48 Pycha A, Mian C, Hofbauer J et al. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998; 159: 265–9 10.1016/S0022-5347(01)64079-5 CASPubMedWeb of Science®Google Scholar 49 Gudjonsson S, Isfoss BL, Hansson K et al. The value of the UroVysion(R) assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007; 54: 402–8 10.1016/j.eururo.2007.11.051 PubMedWeb of Science®Google Scholar 50 Daniely M, Rona R, Kaplan T et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and followup of bladder cancer in patients with benign urine cytology. Cancer 2007; 111: 517–24 10.1002/cncr.23119 CASPubMedWeb of Science®Google Scholar 51 Kipp BR, Karnes RJ, Brankley SM et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005; 173: 401–4 10.1097/01.ju.0000149825.83180.a4 PubMedWeb of Science®Google Scholar 52 Mengual L, Marin-Aguilera M, Ribal MJ et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with Bacillus Calmette-Guerin therapy. Eur Urol 2007; 52: 752–9 10.1016/j.eururo.2007.03.001 PubMedWeb of Science®Google Scholar 53 Whitson J, Greene KG, Carroll PR, Konety BR. Decreasing time to detection: use of fluorescence in situ hybridization in patients with high risk superficial bladder tumors undergoing intravesical therapy. J Urol 2008; 179: 69 10.1016/S0022-5347(08)60203-7 Web of Science®Google Scholar 54 Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Asfaq S. Prospective Evaluation of the clinical utility of reflex fluorescence in situ hybridization assay in patients with atypical cytology for detection of urothelial carcinoma of the bladder. J Urol 2008; 179: 2164–9 10.1016/j.juro.2008.01.105 PubMedWeb of Science®Google Scholar 55 Olweny E, Garcia M, Carroll PR, Konety BR. FISH vs. cytology in post cystectomy surveillance. J Urol 2008; 179: 69 10.1016/S0022-5347(08)60204-9 Web of Science®Google Scholar 56 Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol 1999; 14: 657–64 CASPubMedWeb of Science®Google Scholar 57 Mungan NA, Vriesema JL, Thomas CM et al. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology 2000; 56: 787–92 10.1016/S0090-4295(00)00798-6 CASPubMedWeb of Science®Google Scholar 58 Schroeder GL, Lorenzo-Gomez MF, Hautmann SH et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004; 172: 1123–6 10.1097/01.ju.0000134347.14643.ab PubMedWeb of Science®Google Scholar 59 Sanchez-Carbayo M, Urrutia M, Silva JM et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001; 165: 1462–7 10.1016/S0022-5347(05)66328-8 CASPubMedWeb of Science®Google Scholar 60 Pariente JL, Bordenave L, Jacob F et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 2000; 163: 1116–9 10.1016/S0022-5347(05)67705-1 CASPubMedWeb of Science®Google Scholar 61 Nisman B, Barak V, Shapiro A et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002; 94: 2914–22 10.1002/cncr.10565 CASPubMedWeb of Science®Google Scholar 62 Nisman B, Biran H, Heching N et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008; 98: 77–9 10.1038/sj.bjc.6604157 CASPubMedWeb of Science®Google Scholar 63 Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE et al. Urinary CYFRA 21-1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007; 51: 1267–74 10.1016/j.eururo.2006.12.019 CASPubMedWeb of Science®Google Scholar 64 NCI. NCI Cancer Screening Overview. Available at: http://www.cancer.gov/cancerinfo/pdq/screening/overview. Accessed April 2008 Google Scholar 65 Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992; 148: 788–90 10.1016/S0022-5347(17)36720-4 CASPubMedWeb of Science®Google Scholar 66 Messing EM, Young TB, Hunt VB et al. Hematuria home screening: repeat testing results. J Urol 1995; 154: 57–61 10.1016/S0022-5347(01)67224-0 CASPubMedWeb of Science®Google Scholar 67 Messing EM, Young TB, Hunt VB et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995; 45: 387–96 10.1016/S0090-4295(99)80006-5 CASPubMedWeb of Science®Google Scholar 68 Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006; 107: 2173–9 10.1002/cncr.22224 PubMedWeb of Science®Google Scholar 69 Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 1998; 82: 825–8 10.1046/j.1464-410X.1998.00879.x CASPubMedWeb of Science®Google Scholar 70 American College of Surgeons. Commission on Cancer National Cancer Database. Available at: http://www.facs.org/cancer/ncdb/index.html. Accessed September 2008 Google Scholar 71 Anonymous. Surveillance, Epidemiology and End Results (SEER) Program (http://www.seer.cancer.gov). SEER Stat Database. Incidence – SEER 9 Regs Public-Use. Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. November 2004 Google Scholar 72 Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666–75 10.1200/JCO.2001.19.3.666 CASPubMedWeb of Science®Google Scholar 73 Lotan Y, Gupta A, Shariat SF et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005; 23: 6533–9 10.1200/JCO.2005.05.516 PubMedWeb of Science®Google Scholar 74 Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol 2004; 172: 1822–4 10.1097/01.ju.0000140500.65341.9a PubMedWeb of Science®Google Scholar 75 Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992; 6: 1–30 10.1016/S0889-8588(18)30360-5 CASPubMedWeb of Science®Google Scholar 76 Zeegers MP, Tan FE, Dorant E, Van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000; 89: 630–9 10.1002/1097-0142(20000801)89:3 3.0.CO;2-Q CASPubMedWeb of Science®Google Scholar 77 Samanic C, Kogevinas M, Dosemeci M et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 2006; 15: 1348–54 10.1158/1055-9965.EPI-06-0021 PubMedWeb of Science®Google Scholar 78 Lotan Y, Shariat SF; NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008; 101: 1362–7 10.1111/j.1464-410X.2008.07473.x CASPubMedWeb of Science®Google Scholar 79 Sarosdy MF, Kahn PR, Ziffer MD et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006; 176: 44–7 10.1016/S0022-5347(06)00576-3 PubMedWeb of Science®Google Scholar 80 Hemstreet GP 3rd , Yin S, Ma Z et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001; 93: 427–36 10.1093/jnci/93.6.427 PubMedWeb of Science®Google Scholar 81 Wu X, Lin J, Grossman HB et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol 2007; 25: 4974–81 10.1200/JCO.2007.10.7557 PubMedWeb of Science®Google Scholar 82 Benoit RM, Gronberg H, Naslund MJ. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 2001; 4: 138–45 10.1038/sj.pcan.4500510 PubMedWeb of Science®Google Scholar 83 Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 137: 132–41 10.7326/0003-4819-137-2-200207160-00015 PubMedWeb of Science®Google Scholar 84 Redaelli A, Cranor CW, Okano GJ, Reese PR. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003; 21: 1213–38 10.2165/00019053-200321170-00001 PubMedWeb of Science®Google Scholar 85 Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA 1995; 274: 881–4 CASPubMedWeb of Science®Google Scholar 86 Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 2005; 14: 529–32 10.1158/1055-9965.EPI-04-0499 PubMedWeb of Science®Google Scholar 87 Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 2006; 107: 982–90 10.1002/cncr.22084 CASPubMedWeb of Science®Google Scholar 88 Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006; 24: 338–43 10.1016/j.urolonc.2005.11.025 PubMedWeb of Science®Google Scholar 89 Ma F, Fleming LE, Lee DJ et al. Mortality in Florida professional firefighters 1972–99. Am J Ind Med 2005; 47: 509–17 10.1002/ajim.20160 CASPubMedWeb of Science®Google Scholar 90 Greene KG, Konety BR, Stoller M. Results from the San Francisco Firefighters bladder cancer screening study. J Urol 2008; 179: 323 10.1016/S0022-5347(08)60945-3 PubMedWeb of Science®Google Scholar Citing Literature Volume102, Issue9bSpecial Issue: Bladder CancerNovember 2008Pages 1234-1241 ReferencesRelatedInformation
Referência(s)